273 related articles for article (PubMed ID: 17413764)
41. Prothrombinase-induced clotting time assay for determination of the anticoagulant effects of unfractionated and low-molecular-weight heparins, fondaparinux, and thrombin inhibitors.
Calatzis A; Peetz D; Haas S; Spannagl M; Rudin K; Wilmer M
Am J Clin Pathol; 2008 Sep; 130(3):446-54. PubMed ID: 18701419
[TBL] [Abstract][Full Text] [Related]
42. Inhibition of intrinsic thrombin generation.
Stief TW
Drug Target Insights; 2006; 1():5-10. PubMed ID: 21901053
[TBL] [Abstract][Full Text] [Related]
43. Anticoagulant characteristics of HD1-22, a bivalent aptamer that specifically inhibits thrombin and prothrombinase.
Müller J; Freitag D; Mayer G; Pötzsch B
J Thromb Haemost; 2008 Dec; 6(12):2105-12. PubMed ID: 18826387
[TBL] [Abstract][Full Text] [Related]
44. Corn trypsin inhibitor in fluorogenic thrombin-generation measurements is only necessary at low tissue factor concentrations and influences the relationship between factor VIII coagulant activity and thrombogram parameters.
van Veen JJ; Gatt A; Cooper PC; Kitchen S; Bowyer AE; Makris M
Blood Coagul Fibrinolysis; 2008 Apr; 19(3):183-9. PubMed ID: 18388496
[TBL] [Abstract][Full Text] [Related]
45. Contact activation of coagulation depends on the maximal lipophilic trigger concentration.
Stief TW
Blood Coagul Fibrinolysis; 2012 Jun; 23(4):296-8. PubMed ID: 22473046
[TBL] [Abstract][Full Text] [Related]
46. [The Choay domain -- the structure responsible for the anticoagulant action of heparins].
Hemker HC; al Dieri R; Wagenvoord R; Béguin S
Bull Acad Natl Med; 2003; 187(1):59-66; discussion 66-7. PubMed ID: 14556454
[TBL] [Abstract][Full Text] [Related]
47. [The effects of various anticoagulants on blood coagulation: with special reference to false positive lupus anticoagulants].
Onda H; Watanabe H
Rinsho Byori; 1989 Dec; 37(12):1385-91. PubMed ID: 2515325
[TBL] [Abstract][Full Text] [Related]
48. The fibrinogen functional turbidimetric assay.
Stief TW
Clin Appl Thromb Hemost; 2008 Jan; 14(1):84-96. PubMed ID: 18160594
[TBL] [Abstract][Full Text] [Related]
49. Monitoring Unfractionated Heparin (UFH) therapy: which Anti-Factor Xa assay is appropriate?
Ignjatovic V; Summerhayes R; Gan A; Than J; Chan A; Cochrane A; Bennett M; Horton S; Shann F; Lane G; Ross-Smith M; Monagle P
Thromb Res; 2007; 120(3):347-51. PubMed ID: 17118432
[TBL] [Abstract][Full Text] [Related]
50. Pharmacodynamic markers in the early clinical assessment of otamixaban, a direct factor Xa inhibitor.
Paccaly A; Ozoux ML; Chu V; Simcox K; Marks V; Freyburger G; Sibille M; Shukla U
Thromb Haemost; 2005 Dec; 94(6):1156-63. PubMed ID: 16411387
[TBL] [Abstract][Full Text] [Related]
51. Laboratory detection of the antiphospholipid syndrome via calibrated automated thrombography.
Devreese K; Peerlinck K; Arnout J; Hoylaerts MF
Thromb Haemost; 2009 Jan; 101(1):185-96. PubMed ID: 19132207
[TBL] [Abstract][Full Text] [Related]
52. Generation of potent coagulation protease inhibitors utilizing zinc-mediated chelation.
Young WB; Sprengeler P; Shrader WD; Li Y; Rai R; Verner E; Jenkins T; Fatheree P; Kolesnikov A; Janc JW; Cregar L; Elrod K; Katz B
Bioorg Med Chem Lett; 2006 Feb; 16(3):710-3. PubMed ID: 16257204
[TBL] [Abstract][Full Text] [Related]
53. Sustained inhibition of whole-blood clot procoagulant activity by inhibition of thrombus-associated factor Xa.
McKenzie CR; Abendschein DR; Eisenberg PR
Arterioscler Thromb Vasc Biol; 1996 Oct; 16(10):1285-91. PubMed ID: 8857926
[TBL] [Abstract][Full Text] [Related]
54. Decreased anticoagulant response to tissue factor pathway inhibitor type 1 in plasmas from patients with lupus anticoagulants.
Liestøl S; Sandset PM; Jacobsen EM; Mowinckel MC; Wisløff F
Br J Haematol; 2007 Jan; 136(1):131-7. PubMed ID: 17092306
[TBL] [Abstract][Full Text] [Related]
55. Effects of the oral, direct factor xa inhibitor rivaroxaban on platelet-induced thrombin generation and prothrombinase activity.
Graff J; von Hentig N; Misselwitz F; Kubitza D; Becka M; Breddin HK; Harder S
J Clin Pharmacol; 2007 Nov; 47(11):1398-407. PubMed ID: 17873238
[TBL] [Abstract][Full Text] [Related]
56. Design and characterization of dipetacompinR10H, a dipetalogastin II-derived, classical competitive thrombin inhibitor.
Bitter T; López M; Nowak G
Thromb Haemost; 2007 Jan; 97(1):139-45. PubMed ID: 17200781
[TBL] [Abstract][Full Text] [Related]
57. Recombinant activated factor VII effectively reverses the anticoagulant effects of heparin, enoxaparin, fondaparinux, argatroban, and bivalirudin ex vivo as measured using thromboelastography.
Young G; Yonekawa KE; Nakagawa PA; Blain RC; Lovejoy AE; Nugent DJ
Blood Coagul Fibrinolysis; 2007 Sep; 18(6):547-53. PubMed ID: 17762530
[TBL] [Abstract][Full Text] [Related]
58. Anticoagulant properties of extracellular slime substance produced by Staphylococcus epidermidis.
Bykowska K; Ludwicka A; Wegrzynowicz Z; Lopaciuk S; Kopeć M
Thromb Haemost; 1985 Dec; 54(4):853-6. PubMed ID: 4089818
[TBL] [Abstract][Full Text] [Related]
59. The ultrasound frequency determines the degree of intrinsic coagulation activation.
Stief TW; Klingmüller V
Blood Coagul Fibrinolysis; 2012 Jul; 23(5):440-4. PubMed ID: 22610138
[TBL] [Abstract][Full Text] [Related]
60. Development of a new laboratory test to evaluate antithrombin resistance in plasma.
Murata M; Takagi A; Suzuki A; Okuyama E; Takagi Y; Ando Y; Kato I; Nakamura Y; Murate T; Matsushita T; Saito H; Kojima T
Thromb Res; 2014 Feb; 133(2):293-8. PubMed ID: 24325876
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
